Ignite Creation Date:
2024-05-06 @ 12:36 AM
Last Modification Date:
2024-10-26 @ 10:52 AM
Study NCT ID:
NCT01611727
Status:
COMPLETED
Last Update Posted:
2012-07-12
First Post:
2012-05-31
Brief Title:
Open-LabelNon-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients
Sponsor:
Pomeranian Medical University Szczecin
Organization:
Pomeranian Medical University Szczecin
Study Overview
Official Title:
Phase II Open-Label Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Cisplatin
Brief Summary:
Among women with a BRCA1 mutation and breast cancer choice of chemotherapy is a critical issue There are emerging data which suggest that mutation carriers may respond differently than non-carriers to particular agents BRCA1-associated cancers differ from non-hereditary cancers for a range of pathologic and molecular factors including tumor grade and histologic appearance Several studies have shown that the response to treatment for women with a BRCA1-associated breast cancer reflects the underlying tumor biology in particular the impairment of the DNA damage response and repair pathways and that it is possible to exploit the sensitivity of BRCA1-associated cancers to DNA damage
It is equally important that the investigators evaluate the benefit of cisplatin in women with disseminated breast cancer including those who have previously been treated with one or more chemotherapy regimens This study is undertaken to evaluate the efficacy of cisplatin chemotherapy in BRCA1 carriers with metastatic breast cancer The primary objective is to determine the objective response rate of cisplatin in BRCA1 carriers with metastatic breast cancer The secondary objectives are to determine 3-year survival and to evaluate the toxicities of cisplatin in BRCA1 carriers with metastatic breast cancer
It is equally important that the investigators evaluate the benefit of cisplatin in women with disseminated breast cancer including those who have previously been treated with one or more chemotherapy regimens This study is undertaken to evaluate the efficacy of cisplatin chemotherapy in BRCA1 carriers with metastatic breast cancer The primary objective is to determine the objective response rate of cisplatin in BRCA1 carriers with metastatic breast cancer The secondary objectives are to determine 3-year survival and to evaluate the toxicities of cisplatin in BRCA1 carriers with metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None